A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai.
The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.